BIA’s Bioscience Forum brought together four experts on cell and gene manufacture to discuss what difficulties are being faced in the industry and how they are reacting to them.
Lonza Pharma & Biotech will expand two of its manufacturing sites to reach the capabilities necessary to produce compounds bio-conjugates through to commercialization.
AGC Biologics has announced plans to build a mammalian cell culture facility in Japan, where the company says demand is growing for antibody-based therapies.
Leaf Expression Systems’ technology enables the manufacture of proteins, vaccines and complex biomolecules without using animal-based products, says recently appointed chief executive.
Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.
Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.
Novo Nordisk will take over the lease of a manufacturing facility in Fremont, California, where the company will make stem cell-based therapies with optionally licensed technology.
Dyadic’s CHO-alternative, the C1 production platform, could reduce time and cost at almost every stage of the cell development and biomanufacturing process, says CEO.
LenioBio and Fraunhofer Institute IME have entered a licensing agreement, allowing LenioBio to commercialize technology into a protein expression platform.
The US Food and Drug Administration has rejected Regeneron’s eye candidate, Eylea, but the biotech says it expects a final regulatory decision within two months.
With $12m in Series C financing, AbSci is looking to tackle the antibody market by accelerating innovation and driving down manufacturing costs using its synthetic biology platform, says CEO.
The US Department of Justice has filed a lawsuit to stop US Stem Cell Clinic from performing autologous stem cell procedures at the request of the US Food and Drug Administration (FDA).
In a move aimed to bolster its immuno-oncology program, Eli Lilly and Company has acquired Armo BioSciences for $50 per share, or approximately $1.6bn.
The patent will help PlantForm Corporation continue to advance its platform for manufacturing antibody and protein drugs, as the company looks to bring products to market, says CEO.
Researchers at the Wyss Institute are teaming up with Cellectis to develop “ultra-safe” human cells resistant to infection – which could enable more effective ways to manufacture protein therapeutics, vaccines, and cell therapies.
There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.
Berkeley Lights has signed a new agreement with Sanofi through which the company will use its Beacon OptoFluidic Platform to fast-track cell line development.
A new vaccine manufacturing facility in Toronto, Canada will boast single-use tech and closed continuous process to help improve productivity and performance, Sanofi says.
Demand for a protein produced from a marine mollusk used as a carrier molecule in therapeutic vaccines has driven Stellar Biotech to expand a facility in LA.
There is a lack of third-party capabilities in the autologous cell therapy space says the new editor of PharmSource ahead of this year’s Interphex Convention.
KBI will provide services to ReForm to further develop and validate its biologic formulation platform and in turn, will gain access to ReForm’s proprietary excipient technologies.
“We need Big Pharma and we are getting Big Pharma,” says Dyadic
Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.
Novartis says the manufacturing method for Regeneron’s wet macular degeneration drug Eylea (aflibercept) infringes on its Lucentis (ranibizumab) patents.
LenioBio will offer cell-free protein expression (CFPE) kits for drug screening through a partnership with DowDuPont, and says it is looking into using the tech for bioprocessing.
Egg adaptation is the biggest culprit in this year’s poor flu vaccine efficacy says Novavax, a firm developing a product based on recombinant protein nanoparticles.
